DNA photo
  Children's Hospital Research  Children's Hospital Labs
Holcombe Grier, MD  Children's logo  Harvard logo
 Holcombe Grier, MD
 X  X
   Department  Hematology/Oncology
   Hospital Title  Clinical Director, Pediatric Oncology
   Academic Title  Professor of Pediatrics
   Phone  617-632-3971
   Fax  617-632-5710
   Email  Holcombe Grier
   Location  Dana-Farber Cancer Institute
44 Binney Street
Boston MA 02115
Research Overview

The Children's Oncology Group a consortium of cancer treatment centers across the United States, Canada, and other countries, works on the design and implementation of studies regarding Ewings' sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. Dr. Grier is an active member of the Bone Tumor Disease Committee and the Soft Tissue Sarcoma Committee of this group.

As part of the Pediatric Solid Tumor group at DFCI and Children's Hospital, Dr. Grier and colleagues help organize laboratory and clinical cross talk.

Dr. Grier is also involved in cancer survivor studies that focus on the late effects of chemotherapy, which are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at DFCI. In addition, he participates in a study of the best application of palliative care through work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.

About Holcombe Grier

Holcombe Grier received his MD from the University of Pennsylvania. He trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina.

He is currently on the executive committee of the Children's Oncology Group, and is a trustee for the American Society of Pediatric Hematology/Oncology. Dr. Grier was named Ray A. Kroc Visiting Professor of Pediatrics at The Hospital for Sick Children and McMaster University, Toronto and Hamilton, Canada in 1999. He received the Charles A. Janeway Award for Excellence in Clinical Teaching of Children's Hospital House Staff in 1992.

Key Publications
  • Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: Pediatric Oncology Group trial. Journal of Clinical Oncology 2002; 20: 426-33.

  • Loh ML, Ahn P, Perez-Atayde AR, Gebhardt MC, Shamberger RC, Grier HE. Treatment of infantile fibrosarcoma with neoadjuvant chemotherapy: results from the Dana-Farber Cancer Institute and Children's Hospital Boston. Journal of Pediatric Hematology and Oncology 2002; 24: 722-726.

  • Ferguson WS, Harris MB, Goorin AM, Gebhardt MC, Link MP, Shochat SJ, Siegal GP, Devidas M, Grier HE. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. Journal of Pediatric Hematology Oncology 2001; 23: 340-348.
 X  X